The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2021 | Myeloma: CAR-T in China
B-cell maturation antigen (BCMA) targeting therapies have revolutionized the myeloma space. Unfortunately, the community is growing increasingly aware of the loss of BCMA and the associated relapse risk of such an event. In this video, Chengcheng Fu, MD, PhD, The First Affiliated Hospital of Soochow University, Suzhou, China, talks on the CAR-T space in China, and where the field may move beyond BCMA. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
